We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 20, 2021

Baseline Circulating Tumor Cell Count as a Prognostic Marker in Metastatic Castrate-Sensitive Prostate Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Clin. Cancer Res 2021 Jan 26;[EPub Ahead of Print], A Goldkorn, C Tangen, M Plets, GJ Morrison, A Cunha, T Xu, JK Pinski, SA Ingles, T Triche, AL Harzstark, M Kohli, GR MacVicar, DA Vaena, AW Crispino, DJ McConkey, PN Lara, MHA Hussain, DI Quinn, NJ Vogelzang, IM Thompson, N Agarwal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading